argenx SE Stock price

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles 16:35:07 27/02/2024 GMT 5-day change 1st Jan Change
377.4 EUR +0.32% Intraday chart for argenx SE +2.28% +9.87%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site

Financials

Sales 2023 * 1.11B 1.2B 95.01B Sales 2024 * 1.62B 1.76B 139B Capitalization 22.34B 24.22B 1,911B
Net income 2023 * -245M -266M -20.95B Net income 2024 * -108M -117M -9.24B EV / Sales 2023 * 18 x
Net cash position 2023 * 2.37B 2.57B 203B Net cash position 2024 * 2.35B 2.55B 201B EV / Sales 2024 * 12.3 x
P/E ratio 2023 *
-88.2 x
P/E ratio 2024 *
-218 x
Employees 843
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.85%
More Fundamentals * Assessed data
Dynamic Chart
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday MT
Argenx Says FDA Accepted for Priority Review Supplemental BLA for Autoimmune Disease Drug Vyvgart Hytrulo MT
US FDA Accepts for Priority Review Argenx's Biologics License Application for Vyvgart Hytrulo MT
Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy CI
Wolfe Research Starts Argenx With Peer Perform Rating MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Thursday Trading MT
Piper Sandler Adjusts argenx's Price Target to $518 From $515, Keeps Overweight Rating MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Halozyme Therapeutics Says Argenx Gets Japan's Approval for Vyvdura to Treat Certain Generalized Myasthenia Gravis Patients MT
Argenx Says Japan Approved Vyvdura Injection for Generalized Myasthenia Gravis MT
Japanese Health Regulator Approves Argenx's Generalized Myasthenia Gravis Treatment MT
More news
1 day+0.32%
1 week+2.28%
Current month+8.20%
1 month+7.09%
3 months-16.52%
6 months-19.57%
Current year+9.87%
More quotes
1 week
364.90
Extreme 364.9
380.50
1 month
345.30
Extreme 345.3
380.50
Current year
328.40
Extreme 328.4
380.50
1 year
271.00
Extreme 271
494.10
3 years
201.40
Extreme 201.4
494.10
5 years
93.05
Extreme 93.05
494.10
10 years
6.23
Extreme 6.23
494.10
More quotes
Managers TitleAgeSince
Founder 52 31/12/07
Director of Finance/CFO 54 29/06/21
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 71 25/04/17
Director/Board Member 73 12/05/15
Director/Board Member 62 27/04/16
More insiders
Date Price Change Volume
27/02/24 377.4 +0.32% 40,579
26/02/24 376.2 -0.37% 47,258
23/02/24 377.6 +1.15% 43,520
22/02/24 373.3 +0.92% 64,876
21/02/24 369.9 +0.98% 60,841

Real-time Euronext Bruxelles, February 27, 2024 at 04:35 pm

More quotes
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
377.4 EUR
Average target price
437 EUR
Spread / Average Target
+15.78%
Consensus
  1. Stock
  2. Equities
  3. Stock argenx SE - Euronext Bruxelles
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW